<DOC>
	<DOCNO>NCT00254917</DOCNO>
	<brief_summary>The present clinical study assess immunogenicity reactogenicity subsequent administration Aventis Pasteur 's DTacP-IPV//PRP~T combine vaccine ( PENTAVAC™/PENTAXIM ) , three-dose primary vaccination 6 , 10 14 week age schedule follow booster vaccination second year life aim cover WHO EPI primary vaccination schedule age diphtheria , tetanus , pertussis , poliomyelitis Hib vaccine . WHO EPI vaccination schedule hepatitis B ( either 0 , 6 14 week 6 , 10 14 week age ) also assess infant bear HBsAg seronegative mother . To assess safety Pentaxim .</brief_summary>
	<brief_title>Assessment Immunogenicity Safety PENTAXIM™ Philippines</brief_title>
	<detailed_description>Open , randomize , multicentric , controlled trial . Infants randomly allocate one two study group follow : Group A : 212 subject receive PENTAXIM™ vaccine 6 , 10 14 week age , recombinant 10 µg hepatitis B vaccine 0 , 6 14 week age . Group B : 212 subject receive PENTAXIM™ recombinant 10 µg hepatitis B vaccines 6 , 10 14 week age . All infant include study receive booster dose PENTAXIM™ vaccine 18-19 month age .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed consent sign one parent ( ) and/or legally accept representative prior first study intervention Healthy male female newborn Age range birth 48 hour life ( include ) Birth weight &gt; 2.5 kg gestational age &gt; 37 week Born HBs antigennegative mother Known previous therapy mother cadaveric pituitary derive human growth hormone Infant presently enrol schedule enrol another clinical trial Infant moderate severe illness , mainly infectious disease Infant fever ( rectal temperature &gt; 38°C axillary temperature &gt; 37.5°C ) Infant severe congenital defect abnormality Uncontrolled coagulopathy blood disorder contraindicate intramuscular injection . Known immunological deficiency ( include know HIV seropositive mother ) Administration vaccine since birth ( BCG ) Previous plan administration immunosuppressive therapy , immunoglobulins /or bloodderived product ( inhaled topical corticoid allow )</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>19 Months</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pentaxim</keyword>
</DOC>